Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study

Article information

Psychiatry Investig. 2022;19(6):500-500

Publication date (electronic) : 2022 June 15

doi : https://doi.org/10.30773/pi.2021.0368e

Seung-Hoon Lee ¹^,^*, Sang Won Jeon ²^,^*, Cheolmin Shin ³, Chi-Un Pae ⁴, Ashwin A. Patkar ⁵, Prakash S. Masand ⁶, Hyonggin An ⁷, Changsu Han ⁸

¹Department of Psychiatry, Veterans Health Service Medical Center, Seoul, Republic of Korea

²Department of Psychiatry, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

³Department of Psychiatry, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea

⁴Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁵Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

⁶Global Medical Education, New York, NY, USA

⁷Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea

⁸Department of Psychiatry, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea

This corrects the article "Acute Efficacy and Safety of Escitalopram Versus Desvenlafaxine and Vortioxetine in the Treatment of Depression With Cognitive Complaint: A Rater-Blinded Randomized Comparative Study" in Volume 19 on page 268.

Psychiatry Investig 2022;19(4):268-280

https://doi.org/10.30773/pi.2021.0368

In the original publication, the affiliation of the fifth author, Ashwin A. Patkar, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA, was incorrect.

The corrected affiliation is as follows: Department of Advance Psychiatry, Rush University Medical Center, Raleigh, NC, USA.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.